THW News and Press, Tekla World Healthcare Fund Shares of Beneficial Interest From 05/21/21

April 8-May 12, 2021, readers mentioned 52 equities in their comments. Some lamented bad news so bad news investments (rogues) mixed with (mostly) favorites. (Hence, these are the ReVFa/Ro.). Ten analyst target estimated TOP NET GAIN reader faves & rogues (ReFa/Ro) FDUS, NVS, BBL,...

For income investors, closed-end funds remain an attractive investment class that covers a variety of asset classes and promise high distributions and reasonable total returns. The market downturn last year exposed the risk of high volatility and deep drawdowns with investing in close...

Healthcare offers essential services that people can't go without, recession or not. The Tekla funds can offer potential in any one of their funds for healthcare exposure. Today we explore the differences and the similarities of the funds. For further details see: Tekla ...

Opportunities and risks in the healthcare sector. The next big areas of innovation in healthcare. Extreme winners and losers in the healthcare sector. For further details see: Building A Healthy Portfolio: Spotlight On Healthcare

THW's offering was undersubscribed. The NAV hit from the offering was relatively small (about -1.2%). We show how one could have taken advantage of the offering to gain 20% free shares of THW. For further details see: THW Rights Offering: Postmortem

The pace of recovery has begun to diverge across economies, with vaccination progress and the scale of government stimulus among the biggest swing factors. Macro disparities have also begun filtering into EPS growth expectations. Cyclically sensitive sectors have dominated the upg...

Nineteen out of 23 CEF sectors are positive on price and 21 out of 23 sectors positive on NAV last week. THW rights offering concludes and was undersubscribed. GUT's and CLM/CRF's rights offerings commentary. IRR will liquidate in another Saba victory, while IID was successful...

Large-cap stocks hit new highs on strong data with record highs set several times during the week and finished very strong rising 300 points on Friday. Discounts on taxable bond CEFs are now very close to NAV. My calculation (which adjusts for the massive premiums on the CLO funds) sh...

The market has been running from all-time high to all-time high. But how expensive is it really? Relative to bonds, equities still look very reasonable on average. Inflationary pressures are rising and will hurt everyone with a large cash allocation. Among equities, there are ...

Some in the investment community are spooked by the upcoming loss of Humira exclusivity. Revenue will likely fall in 2023, but the acquisition of Allergan, as well as the growth of revenue from Rinvoq, Skyrizi and Imbruvica should fill the gap. Management guides for high single-di...